bionest immuno-oncology capabilitiesbionest.com/wp-content/uploads/2016/05/2016... · 2016 –...
TRANSCRIPT
1
Bionest Immuno-Oncology Capabilities
ARE YOU POSITIONED FOR SUCCESS
IN NEXT-GENERATION IMMUNO-
ONCOLOGY?
Bionest Immuno-Oncology Capabilities 2016 – Slide 3
IO Frenzy Raises Key Strategic Questions
PD-1 / PD-L1
Next-Gen
Checkpoints: IDO-1, OX-40, GITR,
LAG-3, TIM-3
2 approved
3 Ph. III
Ph. I-II = 10+ What combination strategy?
What opportunity for my early stage PD-(L)1?
Biomarker or no biomarker?
How to differentiate my PD-(L)1?
15+ in clinical trials
>40 pre-clinical
Novel-combo? PD-(L)1 combo? Mono?
What opportunities for my asset?
Biomarker or no biomarker?
How can I move quickly?
As IO moves beyond the first generation of Yervoy, Opdivo, and Keytruda, more companies are investing in IO…
…opportunities abound, but the field is moving fast and opportunities
will close quickly.
Bionest Immuno-Oncology Capabilities 2016 – Slide 4
Keys to a Successful IO Strategy
DEFINE ALTERNATIVES TO ADDRESS HIGH
IMPACT OPPORTUNITIES
Evaluate when and where to leverage combinations, whether you need a biomarker / CDx strategy, and how to maximize your asset or portfolio value
KNOW THE OPPORTUNITIES
The IO space is becoming increasingly crowded, and opportunity windows may not remain open for long
BUILD A ROBUST IO PORTFOLIO…
OR BECOME PARTNER OF CHOICE
Developing an IO focused Corporate Development Strategy is critical, whether you plan to build internally, invest in external opportunities, or focus on
external collaborations
Bionest Immuno-Oncology Capabilities 2016 – Slide 5
What Can Bionest Do For You?
DEFINE STRATEGIC
ALTERNATIVES
MAPPING
OPPORTUNITIES
CORPORATE
DEVELOPMENT STRATEGY
In-depth IO landscape assessment
Competitor strategies and future scenarios
Mapping & prioritization of opportunity areas
Future landscape and timing of opportunity windows
How to address high impact opportunities
Combination strategy
Biomarker / CDx strategy
How and when to leverage your internal PD-(L)1
Differentiating delivery / formulation strategy
Building a competitive IO portfolio
Search & Scout to identify external opportunities
Partnering strategy
Bionest Immuno-Oncology Capabilities 2016 – Slide 6
Bionest has a Strong Track Record in Immuno-Oncology Multiple Big Pharma and Biotech Clients
Numerous Companies Have Trusted Bionest With IO-Related Projects
Bionest Has Worked Extensively in Immuno-Oncology
In Multiple Treatment Modalities... … And Across Various Therapeutic Areas
Checkpoint Modulators
CAR-T / TCR
BiTEs
Vaccines
Solid Tumors
Melanoma, NSCLC, RCC, H&N, Gastric, HCC, CRC,
Breast, Ovarian, Prostate, Glioblastoma etc.
Heme Malignancies
B and T Cell NHL, CLL, MDS, Multiple Myeloma,
Leukemia, etc.
Bionest Immuno-Oncology Capabilities 2016 – Slide 7
Bionest has a Strong Track Record in Immuno-Oncology Selected Project Examples
Immuno-Oncology Portfolio Strategy Immuno-Oncology Combination Strategy
In-depth review of IO landscape and clear
understanding of opportunity areas, including
competition, timelines, and efficacy
requirements
Workshop session to prioritize opportunities
and define optimal strategy to maximize
success of the program
Recommended IO strategy including a
presentation for Sr. Management
Developed understanding of the evolving IO
combination landscape
Identified opportunities to enhance the value
proposition of each of the client’s therapies to
drive differentiation and gain leadership
Bionest prioritized potential combination
partners and provided rationales for a
mutually beneficial partnership
Company Strategies
Strategy for Opportunity Area #1
Bionest Immuno-Oncology Capabilities 2016 – Slide 8
Bionest has a Strong Track Record in Immuno-Oncology Extensive Thought Leadership
“Immunotherapy: Big Pharma’s Seductive Embrace”
IN VIVO, Dec. 2014
“Companies are…setting up combination trials early in
clinical development…This notion of seeking synergy from
the get-go is a dramatic shift in how cancer drugs are
developed, with strong implications for partnering, pricing,
and life cycle management”
SEPTEMBER 2015
“Immuno-Oncology Brings New
Opportunities for Developers of
Targeted Cytotoxics”
Personalized Medicine in Oncology
Selected Articles and Presentations
To read these articles and more, visit http://bionest.com/publications/publications/
2016
“Time to be Savvy for
Next-Generation
Immuno-oncology”
Article in Progress
2016
“Can CDx Save the Next-
Generation of Immuno-
Oncology?”
Article in Progress
First-generation IO agents have, for the most part, been widely approved. After the
focus on precision medicine for molecular therapies, it has
failed to make its way into IO thus far. However, the IO space is poised to become increasingly
complex. Experts recognize that biomarker approaches will become increasingly important, but how this will play out and who will drive this remains to
be seen.
Opdivo and Keytruda have been approved and incorporated into
standard-of-care in several indications, with other
approvals on the horizon. Companies are capitalizing on
immuno-oncology’s (IO) success, pushing forward with
additional PD-1/L1 inhibitors as well as next-generation
therapies. These companies face a highly competitive and
complex market, where past strategies may prove obsolete and more savvy bets may drive
success.
Bionest Immuno-Oncology Capabilities 2016 – Slide 9
Bionest is a Global Consulting Firm With an Experienced Management Team
Bionest Professional Staff: Majority of the team have a Ph.D. and / or MBA degree
Europe
Rachel Laing Manager Basel
Anne-Sophie Demange Manager Paris
Alain Gilbert Co-Chairman Paris
Asia
Yasuhiro Komatsu
Senior Advisor
Tokyo
Additional Strategic partner in China
America
Mary Koto Founder San Diego
Olivier Lesueur Managing Director New York
Bob Easton Co-Chairman New York
Additional Strategic partner in South America
Bionest Immuno-Oncology Capabilities 2016 – Slide 10 10 10
19, rue du Général Foy 75008 Paris
France
Tel: +33 1 58 05 14 00
380 Lexington Ave, 43rd Floor New York, NY 10168
USA
Tel: +1 612 212 3030
www.bionest.com